ETON - Company ID 0001710340
The table below shows Eton Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $24.27M | $22.46M | $18.93M | $17.28M | $10.32M | $9.07M |
| Cost of revenue | $9.53M | $14.60M | $7.00M | $7.42M | $4.02M | $3.45M |
| Gross profit | $14.73M | $7.86M | $11.92M | $9.86M | $6.30M | $5.63M |
| R&D | $1.88M | $1.11M | $3.71M | $1.16M | $505.00K | $2.97M |
Eton Pharmaceuticals, Inc. reported annual revenue of $79.95M for fiscal year 2025. That is up 104.9% from $39.01M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $959.00K (FY 2019) to $79.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $10.45M | $8.11M | $9.69M | $9.17M | $5.29M | $5.59M |
| Operating income | $2.41M | -$1.36M | -$1.48M | -$470.00K | $509.00K | -$2.94M |
| Income tax | $20.00K | -$28.00K | $66.00K | $74.00K | -$126.00K | $54.00K |
| Net income | $1.55M | -$1.93M | -$2.58M | -$1.57M | $627.00K | -$3.04M |
| EPS (diluted) | $0.05 | -$0.07 | - | -$0.06 | $0.02 | -$0.12 |